Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Attikon Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with uncontrolled severe eosinophilic asthma placed under treatment with mepolizumab, i.e. in patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants
You may not be if
Patient refusal to participate in the study
Clareo Health | Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
